Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern

This publication has 25 references indexed in Scilit:

• Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
  The Lancet, 2021
• The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021
  MMWR. Morbidity and Mortality Weekly Report, 2021
• Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review
  Annals of Oncology, 2021
• Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis
  European Journal of Cancer, 2021
• Nosocomial outbreak caused by the SARS-CoV-2 Delta variant in a highly vaccinated population, Israel, July 2021
  Eurosurveillance, 2021
• A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study
  ESMO Open, 2021
• Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection
  Science Advances, 2021
• Antibody evasion by the P.1 strain of SARS-CoV-2
  Cell, 2021
• Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020
  Eurosurveillance, 2020
• The STROBE guidelines
  Saudi Journal of Anaesthesia, 2019